Bridget Finn is an American art dealer and gallerist serving as the director of Art Basel Miami Beach since 2023. In 2022, she cofounded Flourish, a fundraising platform for the STXBP1 Foundation.

Life edit

Finn was raised in Grosse Pointe, Michigan.[1] She earned a B.F.A. from the College for Creative Studies in 2005.[1][2]

Finn worked at the Anton Kern gallery in New York.[1] From 2010 to 2013, she was director of strategic planning and projects at Independent Curators International.[3] For four years, Finn was the director of contemporary programming at Mitchell-Innes & Nash.[1] In October 2017, she joined Reyes Projects, a gallery in Birmingham, Michigan as its managing director.[1]

In July 2020, Finn and musician Sam Beaubien had a daughter while living in Lafayette Park, Detroit.[4] They returned to Grosse Pointe in December that year.[4] Their daughter was diagnosed with a STXBP1 disorder on November 15, 2021.[5] On Rare Disease Day in 2022, they launched Flourish, a fundraising platform for the STXBP1 Foundation on Rare Disease Day.[4] The same year, Flourish partnered with Christie's in New York to host an art auction fundraiser.[5]

In July 2023, Finn was selected as the incoming director of Art Basel Miami Beach.[3] She began the role in September.[3]

References edit

  1. ^ a b c d e Freeman, Nate (October 30, 2017). "Bridget Finn Joins Michigan's Reyes Projects as Managing Director". ARTnews. Retrieved 2023-07-22.
  2. ^ Kobersmith, Kim (2022-11-16). "Interview: Gallery Owner Bridget Finn". UnderMain. Retrieved 2023-07-22.
  3. ^ a b c Kinsella, Eileen (2023-07-19). "Veteran Gallerist Bridget Finn Appointed Director of Art Basel Miami Beach". Artnet. Retrieved 2023-07-22.
  4. ^ a b c McVeigh, Jody (2022-09-29). "In full FLOURISH: Local fundraising platform partners with Christie's for auction". Grosse Pointe News. Retrieved 2023-08-21.
  5. ^ a b Donoghue, Katy (September 28, 2022). "Gallerist Bridget Finn Launches Benefit Sale Inspired by Her Daughter and Rare Disease Diagnosis". Whitewall. Retrieved 2023-08-21.